Tearsheet

BioNexus Gene Lab (BGLC)

Market Price (2/15/2026): $2.12 | Market Cap: $3.8 Mil
Sector: Materials | Industry: Specialty Chemicals

BioNexus Gene Lab (BGLC)

Market Price (2/15/2026): $2.12
Market Cap: $3.8 Mil
Sector: Materials
Industry: Specialty Chemicals

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -71%	Weak multi-year price returns 2Y Excs Rtn is -86%, 3Y Excs Rtn is -164%	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -2.6 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -27%
1	Valuation becoming less expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -61%		Weak revenue growth Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -5.7%, Rev Chg QQuarterly Revenue Change % is -3.3%
2	Megatrend and thematic drivers Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, and Personalized Diagnostics.		Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -29%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -29%
3			Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -64%
4			High stock price volatility Vol 12M is 1186%
5			Key risks BGLC key risks include [1] significant financial instability and a history of Nasdaq delisting risk, Show more.

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -71%
1	Valuation becoming less expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -61%
2	Megatrend and thematic drivers Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, and Personalized Diagnostics.
3	Weak multi-year price returns 2Y Excs Rtn is -86%, 3Y Excs Rtn is -164%
4	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -2.6 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -27%
5	Weak revenue growth Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -5.7%, Rev Chg QQuarterly Revenue Change % is -3.3%
6	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -29%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -29%
7	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -64%
8	High stock price volatility Vol 12M is 1186%
9	Key risks BGLC key risks include [1] significant financial instability and a history of Nasdaq delisting risk, Show more.

Valuation, Metrics & Events

	2/15/26	2025	2024	2023	2022	2021
Share Price CYE	$2.12	$3.95	$0.28	$0.53	$11.40	$25.56
Market Cap CYE ($ Mil)	3.8	7.1	0.5	0.9	16.5	36.5
Total Debt ($ Mil)	0.2	0.2	0.2	0.1	0.0	0.1
Total Cash ($ Mil)	2.9	2.9	4.1	6.1	1.5	1.7
Enterprise Value ($ Mil)	1.1	7.3	0.7	1.0	16.5	36.6
Valuation Ratios
P/S TTM	0.4	0.7	0.1	0.1	1.5	2.6
P/EBIT TTM	-1.6	-3.0	-0.6	-0.3	506.6	42.8
P/E TTM	-1.7	-3.1	-0.5	-0.3	-150.4	74.7
P/FCF TTM	-1.4	-2.6	-0.2	-1.2	31.8	1,029.1
Sector Ratios
P/S TTM (Sector)	1.8	1.5	1.4	1.4	1.2	1.5
P/EBIT TTM (Sector)	7.3	6.5	6.3	6.8	4.9	7.4
P/E TTM (Sector)	-0.4	-0.5	4.0	8.7	5.4	9.0
P/FCF TTM (Sector)	6.9	6.1	7.7	1.2	2.8	7.4

	2/15/26	2025	2024
Share Price CYE	$2.12	$3.95	$0.28
Market Cap CYE ($ Mil)	3.8	7.1	0.5
Total Debt ($ Mil)	0.2	0.2	0.2
Total Cash ($ Mil)	2.9	2.9	4.1
Enterprise Value ($ Mil)	1.1	7.3	0.7
Valuation Ratios
P/S TTM	0.4	0.7	0.1
P/EBIT TTM	-1.6	-3.0	-0.6
P/E TTM	-1.7	-3.1	-0.5
P/FCF TTM	-1.4	-2.6	-0.2
Sector Ratios
P/S TTM (Sector)	1.8	1.5	1.4
P/EBIT TTM (Sector)	7.3	6.5	6.3
P/E TTM (Sector)	-0.4	-0.5	4.0
P/FCF TTM (Sector)	6.9	6.1	7.7

	BGLC	S&P 500
REVENUE GROWTH	VERY POOR
Rev LTM ($ Bil)	0.0
Rev Chg Q	-3.3%	7.5%
Rev Chg LTM	2.2%	6.5%
Rev Chg 3Y Avg	-5.7%	5.6%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	-0.0
CFO LTM ($ Bil)	-0.0
Net Inc LTM ($ Bil)	-0.0
Op Mgn LTM	-26.9%	18.8%
CFO/Rev LTM	-28.8%	20.7%
Net Inc Mgn	-24.3%	12.8%
VALUATION	VERY LOW
P/S	0.4	3.4
P/CFO	-1.4	16.4
P/FCF	-1.4	21.5
P/E	-1.7	25.0
STABILITY	VERY GOOD
Debt/Equity	0.05	0.20
Cash/Assets	0.38	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
Registered Users on Investee's Platform	145000+	4182024	Link
Individual Health Records on Investee's Platform	340000+	4182024	Link
Onboarded Healthcare Providers and Corporations on Investee's Platform	30+	4182024	Link
Major Customer Concentration (as % of Q2 Revenue)	11%	8182025	Link
Number of Patents (Medical)	0	8292024	Link

null

Price Chart

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

BioNexus Gene Lab (BGLC) stock has lost about 60% since 10/31/2025 because of the following key factors:

1. Persistent Nasdaq Delisting Risk and Financial Instability. BioNexus Gene Lab (BGLC) has faced ongoing challenges in meeting Nasdaq's minimum bid price requirement, receiving a temporary exception until May 1, 2025, to regain compliance. The company's continued financial struggles, marked by consistent operating losses, have contributed to a precarious market capitalization and a low price-to-book ratio, indicating underlying financial instability.

2. Significant Shareholder Dilution from Capital Raising Activities. In November and December 2025, BioNexus Gene Lab announced several capital-raising initiatives that introduced substantial potential for shareholder dilution. These included the filing of a $100 million shelf registration, the establishment of a $20 million at-the-market (ATM) program, and a $500 million equity purchase agreement with ARC Group International Ltd. While these facilities aim to provide financial flexibility, each capital call from the equity facility or sales through the ATM program involve issuing new shares, which typically exerts downward pressure on the stock price and dilutes existing shareholder value.

Show more

Stock Movement Drivers

Fundamental Drivers

The -60.9% change in BGLC stock from 10/31/2025 to 2/15/2026 was primarily driven by a -60.5% change in the company's P/S Multiple.

(LTM values as of)	10312025	2152026	Change
Stock Price ($)	5.42	2.12	-60.9%
Change Contribution By:
Total Revenues ($ Mil)	10	9	-0.9%
P/S Multiple	1.0	0.4	-60.5%
Shares Outstanding (Mil)	2	2	0.0%
Cumulative Contribution			-60.9%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 2/15/2026

	Return	Correlation
BGLC	-60.5%
Market (SPY)	-0.0%	36.4%
Sector (XLB)	24.5%	9.4%

Fundamental Drivers

The -69.4% change in BGLC stock from 7/31/2025 to 2/15/2026 was primarily driven by a -70.1% change in the company's P/S Multiple.

(LTM values as of)	7312025	2152026	Change
Stock Price ($)	6.93	2.12	-69.4%
Change Contribution By:
Total Revenues ($ Mil)	9	9	2.1%
P/S Multiple	1.3	0.4	-70.1%
Shares Outstanding (Mil)	2	2	0.0%
Cumulative Contribution			-69.4%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2025 to 2/15/2026

	Return	Correlation
BGLC	-69.1%
Market (SPY)	8.2%	22.6%
Sector (XLB)	22.1%	-0.9%

Fundamental Drivers

The -48.0% change in BGLC stock from 1/31/2025 to 2/15/2026 was primarily driven by a -49.1% change in the company's P/S Multiple.

(LTM values as of)	1312025	2152026	Change
Stock Price ($)	4.08	2.12	-48.0%
Change Contribution By:
Total Revenues ($ Mil)	9	9	2.2%
P/S Multiple	0.8	0.4	-49.1%
Shares Outstanding (Mil)	2	2	0.0%
Cumulative Contribution			-48.0%

LTM = Last Twelve Months as of date shown

Market Drivers

1/31/2025 to 2/15/2026

	Return	Correlation
BGLC	-47.5%
Market (SPY)	14.3%	-0.7%
Sector (XLB)	21.8%	-5.3%

Fundamental Drivers

The -98.2% change in BGLC stock from 1/31/2023 to 2/15/2026 was primarily driven by a -97.4% change in the company's P/S Multiple.

(LTM values as of)	1312023	2152026	Change
Stock Price ($)	120.00	2.12	-98.2%
Change Contribution By:
Total Revenues ($ Mil)	11	9	-16.5%
P/S Multiple	15.3	0.4	-97.4%
Shares Outstanding (Mil)	1	2	-19.4%
Cumulative Contribution			-98.2%

LTM = Last Twelve Months as of date shown

Market Drivers

1/31/2023 to 2/15/2026

	Return	Correlation
BGLC	-98.2%
Market (SPY)	74.0%	-0.7%
Sector (XLB)	32.9%	-4.4%

Return vs. Risk

Price Returns Compared

	2021	2022	2023	2024	2025	2026	Total [1]
Returns
BGLC Return	-7%	-55%	-95%	-47%	41%	-49%	-99%
Peers Return	-17%	-51%	18%	37%	73%	-7%	6%
S&P 500 Return	27%	-19%	24%	23%	16%	-0%	82%
Monthly Win Rates [3]
BGLC Win Rate	33%	25%	25%	50%	33%	0%
Peers Win Rate	50%	32%	50%	52%	55%	50%
S&P 500 Win Rate	75%	42%	67%	75%	67%	50%
Max Drawdowns [4]
BGLC Max Drawdown	-57%	-66%	-97%	-57%	-92%	-51%
Peers Max Drawdown	-26%	-64%	-22%	-30%	-27%	-10%
S&P 500 Max Drawdown	-1%	-25%	-1%	-2%	-15%	-1%

[1] Cumulative total returns since the beginning of 2021
[2] Peers: GH, EXAS, NTRA, ILMN, VCYT.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/13/2026 (YTD)

How Low Can It Go

Unique Key	Event	BGLC	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-98.8%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	8554.5%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	Not Fully Recovered days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-60.0%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	150.0%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	38 days	148 days

Compare to GH, EXAS, NTRA, ILMN, VCYT

In The Past

BioNexus Gene Lab's stock fell -98.8% during the 2022 Inflation Shock from a high on 3/3/2021. A -98.8% loss requires a 8554.5% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About BioNexus Gene Lab (BGLC)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

N/A

AI Analysis | Feedback

Here are 1-2 brief analogies for BioNexus Gene Lab (BGLC):

Like a specialized Invitae (before its acquisition), focused on advanced genetic and molecular diagnostic testing.
A developing Exact Sciences, building out genomic-based tests for early disease detection and personalized medicine.

AI Analysis | Feedback

Genetic Testing Services: Provides comprehensive genetic analysis to identify predispositions to diseases, drug responses, and personal health insights.
Precision Medicine Solutions: Offers personalized healthcare strategies and treatment recommendations tailored to an individual's unique genetic profile.
Clinical Diagnostic Laboratory Services: Operates advanced laboratories providing a broad spectrum of diagnostic tests for various medical conditions.

AI Analysis | Feedback

BioNexus Gene Lab (BGLC) serves a diverse customer base, identifying the following as its primary customer categories, according to its SEC filings:

Individual Patients: These are direct consumers who utilize BGLC's clinical laboratory services for various diagnostic tests, including but not limited to COVID-19 testing, infectious disease screening, and pharmacogenomics.
Healthcare Providers: This category includes a range of medical entities such as physician offices, clinics, hospitals, and urgent care centers that partner with BGLC to process diagnostic tests for their patients.
Long-term Care Facilities: The company provides its diagnostic testing services to facilities like nursing homes and assisted living centers, supporting the health monitoring and care of their residents.

The company's public filings do not disclose specific names of major organizational customers within the healthcare provider or long-term care facility categories.

AI Analysis | Feedback

null

AI Analysis | Feedback

Su-Leng Tan (Lee), Chief Executive Officer

Mr. Su-Leng Tan, also known as Lee, has served as the Chief Executive Officer and Director of BioNexus Gene Lab Corp. since December 11, 2023. He previously held the position of Acting Chief Financial Officer for the company.

Chong Set Fui (Angeline), Chief Financial Officer

Ms. Chong Set Fui (Angeline) was appointed Chief Financial Officer and Principal Financial Officer of BioNexus Gene Lab Corp. on June 17, 2025. She brings over 25 years of senior financial leadership experience, including her tenure as the Chief Financial Officer of Avillion Berhad from 2013 until November 2024. Ms. Chong is a member of the Association of Chartered Certified Accountants (ACCA) and the Malaysian Institute of Accountants (MIA), possessing expertise in corporate financial reporting, internal controls, and regional operations oversight.

Muhammad Azrul bin Abdul Hamid, Director

Muhammad Azrul bin Abdul Hamid serves as a Director for BioNexus Gene Lab Corp. He was appointed to the Audit Committee and as the Compensation Committee Chair on December 11, 2023.

Jook Yuen Low, Independent Director

Jook Yuen Low is an Independent Director of BioNexus Gene Lab Corp.

Chee Keong Yap, Independent Director

Chee Keong Yap is an Independent Director of BioNexus Gene Lab Corp.

AI Analysis | Feedback

Key Risks to BioNexus Gene Lab (BGLC)

Ongoing Financial Instability and Delisting Risk: BioNexus Gene Lab Corp. faces significant financial challenges, including persistent ongoing losses despite revenue streams from its subsidiary. This financial strain has previously placed the company at risk of being delisted from Nasdaq due to a low share price. Although BGLC recently regained compliance with Nasdaq's minimum bid requirement after a reverse stock split, the underlying financial instability remains a critical concern.
Market Volatility: As a penny stock, BioNexus Gene Lab Corp. is susceptible to high volatility and stability issues, which inherently makes it a risky investment. This risk is further amplified by operating within the biotechnology sector, which is known for its high market volatility influenced by factors such as market sentiment, competition, and technological advancements.
Declining Earnings and Profitability Challenges: The company has reported ongoing losses and a significant decline in earnings, with a 63% decrease per year over the past five years and a continuous fall year-over-year for four consecutive quarters. This trend indicates fundamental challenges in achieving and sustaining profitability, which could further exacerbate its financial instability.

AI Analysis | Feedback

null

AI Analysis | Feedback

BioNexus Gene Lab (BGLC) operates primarily in the field of RNA-based blood diagnostics for the early detection of various diseases, including a panel of eight common cancers, two inflammatory diseases, and osteoarthritis. Their operations are concentrated in Malaysia and the broader Southeast Asia region.

Addressable Markets for Main Products/Services

Malaysia Genetic Testing Market: This market was valued at approximately USD 100.76 million in 2021 and is projected to reach USD 316.51 million by 2032, demonstrating a Compound Annual Growth Rate (CAGR) of 21.94% from 2025 to 2032. Another estimate indicates the Malaysia Genomic Diagnostics Market was valued at USD 52.49 million in 2023 and is predicted to grow to USD 154.74 million by 2030, at a CAGR of 16.7%. Similarly, the Malaysia Genomics market was valued at around USD 52.5 million in 2023 and is projected to reach USD 154.7 million by 2030, with a CAGR of 16.70%.
Southeast Asia Genetic Testing Market (Asia-Pacific Region): The broader Asia-Pacific genetic testing market, which includes Southeast Asia, was estimated at USD 2.28 billion in 2024 and is projected to reach USD 14.16 billion by 2033, growing at a CAGR of 22.5% during the forecast period of 2025-2033. Another source states the Asia-Pacific genetic testing market is expected to reach USD 4.87 billion in 2025 and grow at a CAGR of 11.90% to reach USD 8.54 billion by 2030. The Asia-Pacific genetic testing market is also anticipated to grow at the fastest CAGR of 22.3% during the forecast period of 2025 to 2032. Specifically for molecular diagnostics, the South East Asia Molecular Diagnostics Market was valued at USD 492.29 million in 2023 and is expected to reach USD 891.87 million by 2031, growing at a CAGR of 7.8% from 2024 to 2031.

BioNexus Gene Lab also has a segment, Chemrex, involved in the sale of chemical raw materials for industrial, medical, appliance, aero, automotive, mechanical, and electronic industries. However, due to the broad nature of "chemical raw materials" and the lack of specific details regarding the types of chemicals or the precise addressable market for their particular offerings within this segment, it is not possible to provide a specific market size for this product line. Therefore, for the chemical raw materials segment, the market size is null.

AI Analysis | Feedback

Expected Drivers of Future Revenue Growth for BioNexus Gene Lab (BGLC)

Over the next 2-3 years, BioNexus Gene Lab (BGLC) is expected to drive revenue growth through several key initiatives:

Expansion into New Markets: BioNexus Gene Lab is actively pursuing domestic and international expansion opportunities to diversify its revenue streams. This includes broadening the reach of its RNA-based genomic diagnostics business, MRNA Scientific, and scaling its specialty materials subsidiary, Chemrex, beyond Southeast Asia into new areas of sustainable development and growth in both upstream and downstream production.
Launch of New and Enhanced Products and Services: The company's commitment to innovation and ongoing research and development efforts are anticipated to yield new products and enhancements to existing services. Recently, BioNexus has launched innovative testing solutions, and it plans to drive the adoption of its non-invasive blood tests designed to screen for 11 major diseases.
Strategic Partnerships: Collaborations with leading healthcare institutions and research organizations are crucial for expanding BioNexus Gene Lab's market reach and enhancing its service offerings. A notable recent development includes a strategic partnership term sheet with BirchBioMed Inc. to advance Birch's FS2 topical platform in Southeast Asia.
Increasing Demand for Genetic Testing and Personalized Medicine: BioNexus is well-positioned to capitalize on the growing market demand for advanced genetic testing solutions and personalized medicine. This broader market trend is expected to contribute significantly to the company's financial success.

AI Analysis | Feedback

Share Issuance

BioNexus Gene Lab Corp filed a shelf registration statement on November 7, 2025, for a continuous offering of up to $3,557,000 of common stock.
The company issued common shares equal to 4.99% of its outstanding common shares to BirchBioMed Inc. as part of a strategic partnership term sheet signed on October 20, 2025.
Prior to its Nasdaq listing, BioNexus Gene Lab Corp conducted an initial public offering (IPO) of up to 1,250,000 shares of common stock at $4.00 per share, yielding gross proceeds of $5,000,000.

Outbound Investments

On October 20, 2025, BioNexus Gene Lab Corp signed a non-binding strategic partnership term sheet with BirchBioMed Inc., which includes BGLC leading Birch's USD $10 million financing round.
MRNA Scientific Sdn. Bhd., a subsidiary of BioNexus Gene Lab Corp, partnered with Protech Builders Sdn. Bhd. to jointly develop and operate biogas plants in Malaysia, with both companies contributing up to RM1,000,000 (approximately USD $235,000) for project development activities.

Capital Expenditures

BioNexus Gene Lab Corp's subsidiary, Chemrex, invested approximately RM 2 million (USD $450,000) to establish a new production facility for high-quality color paste, which began operations in late September 2024.

Interactive Breakdown

null

null

Better Bets vs. BioNexus Gene Lab (BGLC)

INDUSTRY: Specialty Chemicals

LIN (4.4%)

Linde

SCCO (3.8%)

Southern Copper

SHW (3.7%)

Sherwin-Williams

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for BGLC: -5.7% | 0.4x)

MCK (13.3% | 0.3x)

McKesson

CVS (7.7% | 0.2x)

CVS Health

CI (14.4% | 0.3x)

Cigna

ELV (8.4% | 0.4x)

Elevance Health

GM (5.8% | 0.4x)

General Motors

Higher Rev Chg LTM (Value for BGLC: 2.2%)

NVDA (65.2%)

NVIDIA

MSFT (16.7%)

Microsoft

GOOGL (15.1%)

Alphabet

AMZN (12.4%)

Amazon.com

AAPL (10.1%)

Apple

Higher Rev Chg 3Y Avg (Value for BGLC: -5.7%)

NVDA (91.6%)

NVIDIA

MSFT (14.4%)

Microsoft

GOOGL (12.5%)

Alphabet

AMZN (11.7%)

Amazon.com

AAPL (4.1%)

Apple

Higher Op Mgn LTM (Value for BGLC: -26.9%)

NVDA (58.8%)

NVIDIA

MSFT (46.7%)

Microsoft

AAPL (32.4%)

Apple

GOOGL (32.0%)

Alphabet

AMZN (11.2%)

Amazon.com

Higher CFO/Rev LTM (Value for BGLC: -28.8%)

MSFT (52.5%)

Microsoft

NVDA (44.4%)

NVIDIA

GOOGL (40.9%)

Alphabet

AAPL (31.1%)

Apple

AMZN (19.5%)

Amazon.com

Higher FCF/Rev LTM (Value for BGLC: -29.2%)

NVDA (41.3%)

NVIDIA

AAPL (28.3%)

Apple

MSFT (25.3%)

Microsoft

GOOGL (18.2%)

Alphabet

AMZN (1.1%)

Amazon.com

Higher Total Yield (Value for BGLC: -59.7%)

MSFT (4.8%)

Microsoft

GOOGL (3.9%)

Alphabet

AMZN (3.6%)

Amazon.com

AAPL (3.5%)

Apple

NVDA (2.3%)

NVIDIA

Best Bets in Materials

What You Pay

P/EBIT (Value for BGLC: -1.6x)

SCCO (25.6x)

Southern Copper

USLM (20.3x)

United States Lime & Minerals

CF (6.9x)

CF Industries

NEU (9.2x)

NewMarket

EXP (12.6x)

Eagle Materials

NEM (13.2x)

Newmont

B (8.7x)

Barrick Mining

CBT (6.5x)

Cabot

CCK (7.0x)

Crown

TGLS (9.6x)

Tecnoglass

P/E (Value for BGLC: -1.7x)

SCCO (42.6x)

Southern Copper

USLM (23.8x)

United States Lime & Minerals

CF (11.1x)

CF Industries

NEU (13.3x)

NewMarket

EXP (17.4x)

Eagle Materials

NEM (19.2x)

Newmont

B (16.1x)

Barrick Mining

CBT (12.9x)

Cabot

CCK (13.5x)

Crown

TGLS (13.7x)

Tecnoglass

What You Get

Rev Chg 3Y Avg (Value for BGLC: -5.7%)

SCCO (7.1%)

Southern Copper

USLM (17.8%)

United States Lime & Minerals

CF (-13.5%)

CF Industries

NEU (-0.4%)

NewMarket

EXP (3.3%)

Eagle Materials

NEM (23.9%)

Newmont

B (16.0%)

Barrick Mining

CBT (-5.7%)

Cabot

CCK (-2.1%)

Crown

TGLS (16.2%)

Tecnoglass

Rev Chg LTM (Value for BGLC: 2.2%)

SCCO (12.7%)

Southern Copper

USLM (20.3%)

United States Lime & Minerals

CF (12.6%)

CF Industries

NEU (-2.2%)

NewMarket

EXP (1.4%)

Eagle Materials

NEM (26.6%)

Newmont

B (31.2%)

Barrick Mining

CBT (-9.6%)

Cabot

CCK (3.3%)

Crown

TGLS (15.7%)

Tecnoglass

Rev Chg Q (Value for BGLC: -3.3%)

SCCO (15.2%)

Southern Copper

USLM (14.1%)

United States Lime & Minerals

CF (21.1%)

CF Industries

NEU (-2.9%)

NewMarket

EXP (-0.4%)

Eagle Materials

NEM (20.0%)

Newmont

B (64.5%)

Barrick Mining

CBT (-11.1%)

Cabot

CCK (4.2%)

Crown

TGLS (9.3%)

Tecnoglass

FCF/Rev 3Y Avg (Value for BGLC: -24.0%)

SCCO (27.0%)

Southern Copper

USLM (25.6%)

United States Lime & Minerals

CF (22.3%)

CF Industries

NEU (18.1%)

NewMarket

EXP (15.1%)

Eagle Materials

NEM (13.8%)

Newmont

B (12.9%)

Barrick Mining

CBT (10.7%)

Cabot

CCK (7.6%)

Crown

TGLS (7.6%)

Tecnoglass

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.8%, and sharpe of 0.46

Latest Trefis Analyses

	Title	Date
0	DASHBOARDS
1	Can BioNexus Gene Lab Stock Recover If Markets Fall?	10/17/2025

	Title
0	ARTICLES

Trade Ideas

Select ideas related to BGLC.

Unique Key

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
CRSR	Corsair Gaming	0.7	48.3%	14.3%
CPS	Cooper-Standard	0.8	32.4%	37.7%
TPH	Tri Pointe Homes	4.0	26.8%	47.3%
RIVN	Rivian Automotive	21.6	26.6%	-10.0%
MGA	Magna International	19.4	18.9%	28.9%
FSLY	Fastly	2.7	13.8%	79.4%
EVMN	Evommune	0.9	13.2%	84.4%
FRMI	Fermi	6.1	11.1%	28.6%
WOLF	Wolfspeed	2.8	10.9%	1.9%
HASI	HA Sustainable Infrastructure Capital	4.9	10.8%	26.3%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
UPB	Upstream Bio	0.5	-31.6%	-67.8%
IRON	Disc Medicine	2.0	-21.9%	-29.5%
BFAM	Bright Horizons Family Solutions	3.8	-18.2%	-34.0%
NUS	Nu Skin Enterprises	0.4	-18.1%	-13.1%
FBIN	Fortune Brands Innovations	6.2	-17.6%	2.6%
PINS	Pinterest	10.5	-16.8%	-40.4%
CALY	Callaway Golf	2.3	-15.0%	-16.8%
DKNG	DraftKings	10.8	-13.5%	-36.9%
TRUP	Trupanion	1.2	-13.0%	-25.2%
RYAN	Ryan Specialty	5.0	-12.8%	-25.0%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
FSLY	Fastly	2.7	113.1%	79.4%
NKTR	Nektar Therapeutics	1.4	93.8%	68.7%
EVMN	Evommune	0.9	82.4%	84.4%
VAL	Valaris	6.8	53.8%	90.4%
ICHR	Ichor	1.6	45.5%	153.8%
IPGP	IPG Photonics	6.5	40.4%	115.0%
CGNX	Cognex	9.9	38.8%	63.4%
CRSR	Corsair Gaming	0.7	31.3%	14.3%
TPH	Tri Pointe Homes	4.0	30.8%	47.3%
CPS	Cooper-Standard	0.8	30.6%	37.7%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
UPB	Upstream Bio	0.5	-66.6%	-67.8%
KD	Kyndryl	2.8	-47.9%	-53.9%
NSP	Insperity	1.0	-34.0%	-33.7%
RPD	Rapid7	0.5	-33.6%	-52.8%
PGY	Pagaya Technologies	1.0	-33.3%	-40.5%
FTRE	Fortrea	0.9	-33.2%	-43.2%
ANGI	Angi	0.4	-31.6%	-37.4%
UPWK	Upwork	1.7	-30.1%	-33.3%
IRON	Disc Medicine	2.0	-29.8%	-29.5%
CLF	Cleveland-Cliffs	5.1	-29.5%	-21.8%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
CRVS	Corvus Pharmaceuticals	1.5	173.6%	142.3%
IPGP	IPG Photonics	6.5	98.5%	115.0%
FSLY	Fastly	2.7	98.4%	79.4%
NKTR	Nektar Therapeutics	1.4	97.6%	68.7%
IBRX	ImmunityBio	5.6	96.9%	200.3%
VAL	Valaris	6.8	75.5%	90.4%
MOD	Modine Manufacturing	11.4	73.1%	62.2%
LITE	Lumentum	39.6	69.7%	52.7%
ICHR	Ichor	1.6	67.5%	153.8%
RAPT	RAPT Therapeutics	1.6	66.2%	70.4%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
UPB	Upstream Bio	0.5	-72.9%	-67.8%
U	Unity Software	7.9	-55.6%	-57.7%
KD	Kyndryl	2.8	-55.5%	-53.9%
FUBO	FuboTV	0.5	-48.1%	-46.8%
HIMS	Hims & Hers Health	3.7	-48.0%	-49.8%
PGY	Pagaya Technologies	1.0	-47.6%	-40.5%
PAR	PAR Technology	0.8	-47.5%	-42.5%
NRGV	Energy Vault	0.5	-47.4%	-30.8%
RPD	Rapid7	0.5	-46.9%	-52.8%
RGNX	Regenxbio	0.4	-46.6%	-44.5%

Peer Comparisons

Peers to compare with:

Financials

	BGLC	GH	EXAS	NTRA	ILMN	VCYT	Median
Name	BioNexus.	Guardant.	Exact Sc.	Natera	Illumina	Veracyte
Mkt Price	2.12	104.80	103.14	205.02	116.13	35.77	103.97
Mkt Cap	0.0	13.1	19.6	28.1	17.7	2.8	15.4
Rev LTM	9	903	3,247	2,117	4,343	495	1,510
Op Inc LTM	-3	-442	-199	-352	816	45	-101
FCF LTM	-3	-262	357	94	931	98	96
FCF 3Y Avg	-2	-300	154	-87	641	61	29
CFO LTM	-3	-223	491	194	1,079	108	151
CFO 3Y Avg	-2	-271	286	-17	798	71	34

Growth & Margins

	BGLC	GH	EXAS	NTRA	ILMN	VCYT	Median
Name	BioNexus.	Guardant.	Exact Sc.	Natera	Illumina	Veracyte
Rev Chg LTM	2.2%	30.4%	17.7%	38.2%	-0.7%	16.4%	17.1%
Rev Chg 3Y Avg	-5.7%	28.0%	16.0%	40.2%	-1.8%	20.5%	18.2%
Rev Chg Q	-3.3%	38.5%	23.1%	34.7%	5.0%	13.8%	18.5%
QoQ Delta Rev Chg LTM	-0.9%	8.9%	5.4%	7.8%	1.3%	3.3%	4.3%
Op Mgn LTM	-26.9%	-49.0%	-6.1%	-16.6%	18.8%	9.0%	-11.4%
Op Mgn 3Y Avg	-24.9%	-73.1%	-7.1%	-27.8%	9.0%	2.0%	-16.0%
QoQ Delta Op Mgn LTM	6.6%	6.6%	-1.1%	-1.7%	0.2%	1.9%	1.0%
CFO/Rev LTM	-28.8%	-24.7%	15.1%	9.2%	24.8%	21.9%	12.2%
CFO/Rev 3Y Avg	-22.5%	-41.4%	9.7%	-5.5%	18.2%	16.2%	2.1%
FCF/Rev LTM	-29.2%	-29.1%	11.0%	4.4%	21.4%	19.8%	7.7%
FCF/Rev 3Y Avg	-24.0%	-45.5%	5.0%	-10.0%	14.6%	13.9%	-2.5%

Valuation

	BGLC	GH	EXAS	NTRA	ILMN	VCYT	Median
Name	BioNexus.	Guardant.	Exact Sc.	Natera	Illumina	Veracyte
Mkt Cap	0.0	13.1	19.6	28.1	17.7	2.8	15.4
P/S	0.4	14.5	6.0	13.3	4.1	5.7	5.9
P/EBIT	-1.6	-33.2	-107.4	-92.1	14.9	113.8	-17.4
P/E	-1.7	-32.8	-94.1	-91.0	20.8	92.9	-17.2
P/CFO	-1.4	-58.7	39.8	144.8	16.4	26.0	21.2
Total Yield	-59.7%	-3.0%	-1.1%	-1.1%	4.8%	1.1%	-1.1%
Dividend Yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FCF Yield 3Y Avg	-260.4%	-6.9%	0.9%	-1.4%	3.1%	2.1%	-0.2%
D/E	0.0	0.1	0.1	0.0	0.1	0.0	0.1
Net D/E	-0.7	0.1	0.1	-0.0	0.1	-0.1	0.0

Returns

	BGLC	GH	EXAS	NTRA	ILMN	VCYT	Median
Name	BioNexus.	Guardant.	Exact Sc.	Natera	Illumina	Veracyte
1M Rtn	-41.7%	-6.5%	0.7%	-11.3%	-18.0%	-14.0%	-12.6%
3M Rtn	-53.2%	11.1%	53.9%	0.4%	-3.8%	-9.1%	-1.7%
6M Rtn	-60.3%	78.0%	126.2%	25.8%	16.0%	18.4%	22.1%
12M Rtn	-42.9%	117.8%	109.2%	18.2%	15.9%	-13.0%	17.0%
3Y Rtn	-96.5%	265.3%	61.7%	314.1%	-43.6%	40.7%	51.2%
1M Excs Rtn	-42.3%	-2.2%	2.2%	-13.0%	-18.0%	-14.4%	-13.7%
3M Excs Rtn	-56.0%	7.3%	51.1%	-1.9%	-4.6%	-15.2%	-3.3%
6M Excs Rtn	-66.1%	67.9%	123.6%	23.7%	10.4%	13.4%	18.6%
12M Excs Rtn	-52.5%	118.0%	91.9%	6.4%	-0.8%	-24.4%	2.8%
3Y Excs Rtn	-163.6%	186.1%	-13.9%	301.6%	-105.4%	-28.0%	-20.9%

FDIC Bank Data

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End	9/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date	11/14/2025	4/15/2025	4/16/2024	3/31/2023	4/6/2022	3/30/2021	3/31/2020
Key Financials
Total Revenue	9	10	10	11	13	11	0
EBITDA	-2	-1	-2	-0	1	1	-0
Operating Income	-3	-2	-3	-0	1	1	-0
Net Income	-2	-2	-3	-0	1	1	-0
EPS	-1.28	-0.90	-1.66	-0.46	0.48	1.44	-0.29
Growth Rates
Total Revenue Growth	2.2%	-2.7%	-10.6%	-18.2%	17.3%	8872.0%	-40.2%
EBITDA Growth	-186.9%	42.8%	-1237.9%	-116.0%	-15.4%	718.5%	-321.2%
Operating Income Growth	-44.8%	36.5%	-957.6%	-127.6%	-17.1%	562.0%	-560.3%
Net Income Growth	-143.9%	39.2%	-638.6%	-147.4%	-31.3%	543.9%	-1031.7%
Margins
EBITDA Margin	-23.0%	-14.9%	-25.4%	-1.7%	8.7%	12.1%	-175.2%
Operating Income Margin	-26.9%	-20.6%	-31.5%	-2.7%	7.9%	11.2%	-217.2%
Net Income Margin	-24.3%	-16.8%	-26.9%	-3.3%	5.6%	9.6%	-194.1%
Cash & Debt
Total Cash	3	4	6	2	2	3	1
Total Debt	0	0	0	0	0	0	0
Net Debt / (Cash)	-3	-4	-6	-2	-2	-3	-1
Cash Flows
Net Cash from Operations	-3	-2	-2	1	0	1	-0
Free Cash from Operations	-3	-2	-2	0	0	0	-0
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4
Period End	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022
Filing Date	11/14/2025	8/18/2025	5/15/2025	4/15/2025	11/15/2024	8/14/2024	5/15/2024	4/16/2024	11/20/2023	8/16/2023	5/9/2023	3/31/2023
Key Financials Quarterly
Total Revenue	3	2	2	3	3	2	2	2	3	3	2	3
Ebitda	-1	-1	-1	-0	-1	0	-0	0	-2	-0	-0	-0
Operating Income	-1	-1	-1	-0	-1	0	-0	-0	-3	-0	-0	-0
Net Income	-1	-1	-1	-0	-1	0	-0	0	-3	-0	-0	-0
EPS	-0.40	-0.34	-0.35	-0.20	-0.75	0.11	-0.06	0.27	-1.56	-0.18	-0.07	-0.32
Key Financials TTM
Total Revenue TTM	9	10	9	10	9	9	10	10	10	10	10	11
Ebitda TTM	-2	-3	-2	-1	-1	-2	-3	-2	-3	-0	-0	-0
Operating Income TTM	-3	-3	-2	-2	-2	-3	-3	-3	-3	-1	-0	-0
Net Income TTM	-2	-3	-2	-2	-1	-2	-3	-3	-3	-1	-0	-0
Growth Rates Quarterly
Total Revenue Growth	-3.3%	14.5%	-10.3%	11.0%	3.0%	-23.1%	0.2%	-20.0%	-0.8%	3.3%	-21.5%	-12.5%
EBITDA Growth	48.8%	-296.0%	-1069.8%	-229.8%	48.4%	217.4%	-91.9%	397.4%	-6246.1%	-122.9%	-142.0%	-142.5%
Operating Income Growth	44.7%	-607.7%	-200.8%	-85.6%	42.0%	150.6%	-304.5%	-86.1%	-3777.2%	-97.3%	-245.9%	-161.0%
Net Income Growth	47.3%	-409.5%	-500.8%	-212.9%	48.4%	176.8%	-50.2%	296.5%	-3271.0%	-87.0%	-504.7%	-275.9%
Margins Quarterly
EBITDA Margin	-25.9%	-25.2%	-27.1%	-14.8%	-49.0%	14.7%	-2.1%	12.6%	-97.9%	-9.6%	-1.1%	-3.4%
Operating Income Margin	-31.9%	-31.0%	-28.8%	-16.8%	-55.7%	7.0%	-8.6%	-10.0%	-99.0%	-10.6%	-2.1%	-4.3%
Net Income Margin	-27.9%	-27.3%	-29.2%	-13.8%	-51.1%	10.1%	-4.4%	13.6%	-102.2%	-10.1%	-2.9%	-5.5%
Cash & Debt
Total Cash	3	3	4	4	4	5	6	6	6	2	2	2
Total Debt	0	0	0	0	0	0	0	0	0	0	0	0
Net Debt / (Cash)	-3	-3	-3	-4	-4	-5	-6	-6	-6	-2	-2	-2
Cash Flows Quarterly
FCF from Operations	-1	-1	-1	0	-2	-1	-0	-1	-1	-0	-0	0
Cash Flows TTM
FCF from Operations TTM	-3	-3	-3	-2	-3	-2	-2	-2	-1	1	0	1
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-34.1%	-30.0%	-29.2%	-18.4%	-68.4%	7.0%	-14.7%	-16.0%	-185.3%	-30.0%	-5.7%	-14.2%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-26.0%	-33.5%	-27.8%	-25.8%	-20.5%	-46.2%	-57.9%	-54.0%	-54.5%	-14.9%	-10.6%	-8.4%

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
Biochemical industry		11	13	11	0
Total		11	13	11	0

Assets by Segment

$ Mil	2024	2023	2022	2021	2020
Chemrex Corporation	7
MRNA Scientific	5
Total	11

Price Behavior

Price Behavior

Market Price	$2.14
Market Cap ($ Bil)	0.0
First Trading Date	09/16/2020
Distance from 52W High	-80.8%
	50 Days	200 Days
DMA Price	$3.48	$4.37
DMA Trend	up	down
Distance from DMA	-38.6%	-51.0%
	3M	1YR
Volatility	70.3%	1,195.3%
Downside Capture	366.67	-322.46
Upside Capture	-87.56	-329.66
Correlation (SPY)	31.3%	-0.7%

BGLC Betas & Captures as of 1/31/2026

	1M	2M	3M	6M	1Y	3Y
Beta	1.09	0.80	1.47	0.99	-0.57	-0.41
Up Beta	-0.59	1.00	2.27	2.40	-0.08	-0.11
Down Beta	4.09	2.96	3.36	3.24	9.74	6.04
Up Capture	-460%	-288%	-160%	-102%	-58%	-7%
Bmk +ve Days	11	22	34	71	142	430
Stock +ve Days	6	12	20	44	95	270
Down Capture	367%	229%	219%	96%	-2550%	-343%
Bmk -ve Days	9	19	27	54	109	321
Stock -ve Days	13	26	37	72	143	409

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with BGLC
BGLC	-30.1%	1,190.4%	1.03	-
Sector ETF (XLB)	22.2%	20.8%	0.86	-5.5%
Equity (SPY)	14.0%	19.4%	0.55	-0.8%
Gold (GLD)	74.3%	25.3%	2.17	-10.1%
Commodities (DBC)	7.0%	16.7%	0.24	-9.7%
Real Estate (VNQ)	7.9%	16.6%	0.28	-15.4%
Bitcoin (BTCUSD)	-29.8%	44.9%	-0.65	-11.0%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with BGLC
BGLC	187.4%	711.9%	1.13	-
Sector ETF (XLB)	9.6%	18.9%	0.40	-3.5%
Equity (SPY)	13.3%	17.0%	0.62	-1.0%
Gold (GLD)	22.1%	17.0%	1.06	-6.9%
Commodities (DBC)	10.5%	18.9%	0.44	-4.9%
Real Estate (VNQ)	5.2%	18.8%	0.18	-6.1%
Bitcoin (BTCUSD)	8.3%	57.2%	0.37	-2.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 10-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with BGLC
BGLC	84.2%	755.8%	1.22	-
Sector ETF (XLB)	12.3%	20.7%	0.53	-2.3%
Equity (SPY)	15.6%	17.9%	0.75	-2.1%
Gold (GLD)	15.3%	15.6%	0.82	-7.4%
Commodities (DBC)	8.1%	17.6%	0.38	-3.8%
Real Estate (VNQ)	6.4%	20.7%	0.27	-7.5%
Bitcoin (BTCUSD)	67.9%	66.7%	1.07	-2.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date	1302026
Short Interest: Shares Quantity	0.0 Mil
Short Interest: % Change Since 1152026	2.1%
Average Daily Volume	0.0 Mil
Days-to-Cover Short Interest	1
Basic Shares Quantity	1.8 Mil
Short % of Basic Shares	1.0%

Returns Analyses

	Title
0	Can BioNexus Gene Lab Stock Recover If Markets Fall?

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
SUMMARY STATS
# Positive	0	0	0
# Negative	0	0	0
Median Positive
Median Negative
Max Positive
Max Negative

SEC Filings

Expand for More

Report Date	Filing Date	Filing
09/30/2025	11/14/2025	10-Q
06/30/2025	08/18/2025	10-Q
03/31/2025	05/15/2025	10-Q
12/31/2024	04/15/2025	10-K
09/30/2024	11/15/2024	10-Q
06/30/2024	08/14/2024	10-Q
03/31/2024	05/15/2024	10-Q
12/31/2023	04/16/2024	10-K
09/30/2023	11/20/2023	10-Q
06/30/2023	08/16/2023	10-Q
03/31/2023	05/09/2023	10-Q
12/31/2022	03/31/2023	10-K
09/30/2022	11/14/2022	10-Q
06/30/2022	08/15/2022	10-Q
03/31/2022	05/16/2022	10-Q
12/31/2021	04/06/2022	10-K

Insider Activity

Expand for Morenull

BGLC Trade Sentinel

Core Investment Debate

BULL VIEW

CORE TENSION

PREVAILING SENTIMENT

BEAR VIEW

Next 6 months: Risks and Catalysts

Timeline	Event & Metric To Watch

Key Events in Last 6 Months

Date	Event	Stock Impact

Risk Management

Position Sizing

null

Diversification Alternatives

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

BioNexus Gene Lab (BGLC)

Market Price (2/15/2026): $2.12 | Market Cap: $3.8 MilSector: Materials | Industry: Specialty Chemicals

BioNexus Gene Lab (BGLC)

Market Price (2/15/2026): $2.12Market Cap: $3.8 MilSector: MaterialsIndustry: Specialty Chemicals

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About BioNexus Gene Lab (BGLC)

Key Risks to BioNexus Gene Lab (BGLC)

Addressable Markets for Main Products/Services

Expected Drivers of Future Revenue Growth for BioNexus Gene Lab (BGLC)

Share Issuance

Outbound Investments

Capital Expenditures

Interactive Breakdown

Better Bets vs. BioNexus Gene Lab (BGLC)

INDUSTRY: Specialty Chemicals

Higher Rev Chg 3Y Avg | Lower P/S (Values for BGLC: -5.7% | 0.4x)

Higher Rev Chg LTM (Value for BGLC: 2.2%)

Higher Rev Chg 3Y Avg (Value for BGLC: -5.7%)

Higher Op Mgn LTM (Value for BGLC: -26.9%)

Higher CFO/Rev LTM (Value for BGLC: -28.8%)

Higher FCF/Rev LTM (Value for BGLC: -29.2%)

Higher Total Yield (Value for BGLC: -59.7%)

SECTOR: Materials

Higher Rev Chg 3Y Avg | Lower P/S (Values for BGLC: -5.7% | 0.4x)

Higher Rev Chg LTM (Value for BGLC: 2.2%)

Higher Rev Chg 3Y Avg (Value for BGLC: -5.7%)

Higher Op Mgn LTM (Value for BGLC: -26.9%)

Higher CFO/Rev LTM (Value for BGLC: -28.8%)

Higher FCF/Rev LTM (Value for BGLC: -29.2%)

Higher Total Yield (Value for BGLC: -59.7%)

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for BGLC: -5.7% | 0.4x)

Higher Rev Chg LTM (Value for BGLC: 2.2%)

Higher Rev Chg 3Y Avg (Value for BGLC: -5.7%)

Higher Op Mgn LTM (Value for BGLC: -26.9%)

Higher CFO/Rev LTM (Value for BGLC: -28.8%)

Higher FCF/Rev LTM (Value for BGLC: -29.2%)

Higher Total Yield (Value for BGLC: -59.7%)

Best Bets in Materials

P/EBIT (Value for BGLC: -1.6x)

P/E (Value for BGLC: -1.7x)

Rev Chg 3Y Avg (Value for BGLC: -5.7%)

Rev Chg LTM (Value for BGLC: 2.2%)

Rev Chg Q (Value for BGLC: -3.3%)

FCF/Rev 3Y Avg (Value for BGLC: -24.0%)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Financials

Growth & Margins

Market Price (2/15/2026): $2.12 | Market Cap: $3.8 Mil
Sector: Materials | Industry: Specialty Chemicals

Market Price (2/15/2026): $2.12
Market Cap: $3.8 Mil
Sector: Materials
Industry: Specialty Chemicals